This CPB is revised to state that sebelipase alfa (Kanuma) is considered medically necessary for persons with a deficiency of lysosomal acid lipase (LAL) enzyme activity confirmed by dried blood spot (DBS) testing and ALT greaterthan or equal to 1.5 times the upper limit of normal ULN (based on the age- and gender-specific normal ranges) on 2 consecutive ALT measurements obtained at least 1 week apart.